Afficher la notice abrégée

Unsuccessful Direct Acting Antiviral Hepatitis C Treatment Among People With HIV: Findings From an International Cohort

dc.rights.licenseopenen_US
dc.contributor.authorHARNEY, Brendan L
dc.contributor.authorSACKS-DAVIS, Rachel
dc.contributor.authorVAN SANTEN, Daniela K
dc.contributor.authorSTEWART, Ashleigh C
dc.contributor.authorMATTHEWS, Gail V
dc.contributor.authorCARSON, Joanne M
dc.contributor.authorKLEIN, Marina B
dc.contributor.authorLACOMBE, Karine
hal.structure.identifierStatistics In System biology and Translational Medicine [SISTM]
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorWITTKOP, Linda
dc.contributor.authorSALMON, Dominque
hal.structure.identifierStatistics In System biology and Translational Medicine [SISTM]
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorLELEUX, Olivier
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorMERCHADOU, Laurence
dc.contributor.authorVAN DER VALK, Marc
dc.contributor.authorSMIT, Colette
dc.contributor.authorPRINS, Maria
dc.contributor.authorBOYD, Anders
dc.contributor.authorBERENGUER, Juan
dc.contributor.authorJARRIN, Inmaculada
dc.contributor.authorRAUCH, Andri
dc.contributor.authorHELLARD, Margaret E
dc.contributor.authorDOYLE, Joseph S
dc.date.accessioned2025-02-19T12:03:03Z
dc.date.available2025-02-19T12:03:03Z
dc.date.issued2025-01-01
dc.identifier.issn1478-3223en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/205024
dc.description.abstractEnBACKGROUND: Historically, hepatitis C virus (HCV) was difficult to treat among people with HIV. However, treatment with direct-acting antivirals (DAAs) results in 90%-95% of people being cured. There is a need to understand why a proportion of people are not cured. We aimed to examine characteristics that may indicate an increased probability of unsuccessful DAA HCV treatment. METHODS: Data were from the International Collaboration on Hepatitis C Elimination in HIV Cohorts. People who commenced DAA HCV treatment between 2014 and 2019 were included. Unsuccessful treatment was defined as a positive HCV RNA test at a person's first RNA test at least 4 weeks (SVR4+) following the end of treatment. Multivariable mixed-effects logistic regression was used to examine characteristics associated with unsuccessful treatment. RESULTS: Of 4468 people who commenced DAA treatment, 4098 (91.7%) had an SVR test 4+ weeks following the end of treatment, 207 (5%) of whom were unsuccessfully treated. Compared to a CD4+ cell count > 500 cells/mm(3), cell counts < 200 (aOR 1.81, 95%CI 1.00-3.29) and between 200 and 349 (aOR 1.95, 95%CI 1.30-2.93) were associated with increased odds of unsuccessful treatment. Among 1921 people with data on injection drug use in the 12 months prior to treatment, there was some evidence that recent injection drug use was associated with increased odds of unsuccessful treatment; however, this was not statistically significant (aOR 1.67, 95%CI 0.99-2.82). CONCLUSIONS: The overwhelming majority of people were successfully treated for HCV. Overall, 5% of those with an SVR4+ test were unsuccessfully treated; this was more likely among people with evidence of immunodeficiency and those who reported recently injecting drugs.
dc.language.isoENen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.subject.enHIV
dc.subject.enClinical Research
dc.subject.enDirect Acting Antiviral
dc.subject.enHepatitis C
dc.subject.enTreatment
dc.title.enUnsuccessful Direct Acting Antiviral Hepatitis C Treatment Among People With HIV: Findings From an International Cohort
dc.title.alternativeLiver Inten_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1111/liv.16203en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed39656170en_US
bordeaux.journalLiver Internationalen_US
bordeaux.page1-13en_US
bordeaux.volume45en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.issue1en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.institutionINRIAen_US
bordeaux.teamSISTM_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.identifier.funderIDAgence Nationale de Recherches sur le Sida et les Hépatites Viralesen_US
bordeaux.identifier.funderIDNational Health and Medical Research Councilen_US
bordeaux.identifier.funderIDCanadian Institutes of Health Researchen_US
hal.identifierhal-04956541
hal.version1
hal.date.transferred2025-02-19T12:03:06Z
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft.jtitle=Liver%20International&amp;rft.date=2025-01-01&amp;rft.volume=45&amp;rft.issue=1&amp;rft.spage=1-13&amp;rft.epage=1-13&amp;rft.eissn=1478-3223&amp;rft.issn=1478-3223&amp;rft.au=HARNEY,%20Brendan%20L&amp;SACKS-DAVIS,%20Rachel&amp;VAN%20SANTEN,%20Daniela%20K&amp;STEWART,%20Ashleigh%20C&amp;MATTHEWS,%20Gail%20V&amp;rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Nom:
BPH_LiverInt_2025_Harney.pdf
Taille:
453.7Ko
Format:
PDF
Voir/Ouvrir
Thumbnail
Nom:
license_rdf
Taille:
914octets
Format:
application/rdf+xml
Voir/Ouvrir

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée